Kidney Stones

"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

In total, 8 of 40 patients who underwent ultrasonic propulsion experienced relapse, compared with 21 of 42 patients who underwent observation.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

In total, the trial plans to enroll 7 patients with PH1 through a single center in China.

Any stone fragmentation was achieved in 88% of patients.

"The great news is that we have now completed recruitment. We actually recruited more than 1700 patients," says Kari A.O. Tikkinen, MD, PhD.

Per Kaplan-Meier estimates, 95.6% of patients who underwent SURE were free of health care consumption events by 12 months, compared with 83.5% of patients who underwent URS.

"We sought to describe the genetic and clinical characteristics for patients undergoing genetic testing at our institution that were referred to genetics from our multidisciplinary stone clinic," says Nicolette G. Payne, MD.

“I think the future is very bright for endourology and pushing the envelope with different minimally invasive techniques to remove stones,” says Marcelino E. Rivera, MD.

"I think the patients that benefit the most are patients that have certain types of stones that potentially are much harder to treat with some of the more minimally invasive types of procedures," says John Michael DiBianco, MD.

"The cases that I've done have been here, at least, have been some of the most, I guess, impactful and really make me proud and happy to be a urologist and to do something [for which] the patients are incredibly grateful," says John Michael DiBianco, MD.

In preclinical studies, META-001-PH demonstrated the ability to reduce urinary oxalate excretion by up to 80%.

"You definitely need to be very adaptable. You have to have a great team," says John Michael DiBianco, MD.

"Kidney stone treatment is all about access," says Joseph Song, MD.

“With the support of the pediatric department and the pediatric urologists I work very closely with, we've been very successful in identifying the right patients,” says John Michael DiBianco, MD.

Data showed that Hispanic patients were consistently underrepresented in clinical trials, while Black participants tended to be overrepresented.

"Stones that recur in children happen about 40% to 50% of the time. That's why the American Urological Association guidelines recommend doing a complete metabolic evaluation in all children," says Katherine Chan, MD, MPH.

“Our final goal is to shift from an episodic care to continuous patient follow-up, allowing us to better understand and manage the evolution of patients over the time,” says Juan Fulla, MD, MSc.

"One day, we're going to have to move away from fee for service, so we'd be wise to try to navigate those waters ahead of time, so we're not left dealing with the aftermath when someone else has implemented it for us," says Ruchika Talwar, MD.

“For us, this approach has the potential to transform the prevention and management of urolithiasis, making health care more precise and personalized,” says Juan Fulla, MD, MSc.

"Anytime we do a PCNL...we always get a CT scan. That's pretty standard," says John Michael DiBianco, MD.

"Certainly, anybody who is a recurrent stone former, or of a young age when they develop their first stone, they automatically get a 24-hour urine test," says Joseph Song, MD.

"As I like to say, 'They are little people with small stones that cause big problems,' " says Katherine Chan, MD, MPH.

"We found that as we got better and better at doing it, the majority of patients now can go home in this fashion. They can go home the day of the procedure with nothing in them," says Mantu Gupta, MD.

"It's my opinion that no patient population benefits more from a miniaturized technique than a pediatric patient," says John Michael DiBianco, MD.

"One of the biggest considerations we have in imaging pediatric patients is radiation exposure," says Katherine Chan, MD, MPH.

"Kidney stones in children are quite a bit different than in adults," says Katherine Chan, MD, MPH.

"This clearance in the US of our new ureteroscopy solution not only demonstrates a market expansion for Ambu; it is a testament to the progressive shift towards single-use solutions within the field of urology," says Britt Meelby Jensen.

"Pediatric patients do have a somewhat heterogeneous or variable presentation of their stone disease. A lot of that is dependent upon their age," says Katherine Chan, MD, MPH.